RU2018131440A - Антагонисты FimH, являющиеся производными маннозы, пригодные для лечения заболевания - Google Patents
Антагонисты FimH, являющиеся производными маннозы, пригодные для лечения заболевания Download PDFInfo
- Publication number
- RU2018131440A RU2018131440A RU2018131440A RU2018131440A RU2018131440A RU 2018131440 A RU2018131440 A RU 2018131440A RU 2018131440 A RU2018131440 A RU 2018131440A RU 2018131440 A RU2018131440 A RU 2018131440A RU 2018131440 A RU2018131440 A RU 2018131440A
- Authority
- RU
- Russia
- Prior art keywords
- mannopyranosyloxy
- methyl
- methylphenyl
- disease
- mannopyranoside
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 9
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 208000019206 urinary tract infection Diseases 0.000 claims 6
- 208000035143 Bacterial infection Diseases 0.000 claims 4
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- -1 α-D-mannopyranosyl Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 2
- HWTRGFBJYZQQQJ-AANPDWTMSA-N (2R,3S,4S,5S,6R)-2-(hydroxymethyl)-6-(2-methyl-5-nitro-4-quinolin-7-yloxyphenoxy)oxane-3,4,5-triol Chemical compound CC1=CC(OC2=CC=C3C=CC=NC3=C2)=C(C=C1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)[N+]([O-])=O HWTRGFBJYZQQQJ-AANPDWTMSA-N 0.000 claims 1
- VMUFHDKHYAGHQP-AANPDWTMSA-N (2R,3S,4S,5S,6R)-2-(hydroxymethyl)-6-(4-isoquinolin-5-yl-2-methylphenoxy)oxane-3,4,5-triol Chemical compound Cc1cc(ccc1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)-c1cccc2cnccc12 VMUFHDKHYAGHQP-AANPDWTMSA-N 0.000 claims 1
- HYFAFWNEPWXODM-AANPDWTMSA-N (2R,3S,4S,5S,6R)-2-(hydroxymethyl)-6-(4-isoquinolin-7-yloxy-2-methyl-5-nitrophenoxy)oxane-3,4,5-triol Chemical compound CC1=CC(OC2=CC=C3C=CN=CC3=C2)=C(C=C1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)[N+]([O-])=O HYFAFWNEPWXODM-AANPDWTMSA-N 0.000 claims 1
- VXDBKXRJILGITM-AANPDWTMSA-N (2R,3S,4S,5S,6R)-2-(hydroxymethyl)-6-[2-methyl-4-(1,2,3,4-tetrahydroisoquinolin-5-yl)phenoxy]oxane-3,4,5-triol Chemical compound Cc1cc(ccc1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)-c1cccc2CNCCc12 VXDBKXRJILGITM-AANPDWTMSA-N 0.000 claims 1
- KTMKCNBRKXDKAM-VROINQGHSA-N (2R,3S,4S,5S,6R)-2-(hydroxymethyl)-6-[2-methyl-4-(2-methyl-3,4-dihydro-1H-isoquinolin-5-yl)phenoxy]oxane-3,4,5-triol Chemical compound CN1CCc2c(C1)cccc2-c1ccc(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)c(C)c1 KTMKCNBRKXDKAM-VROINQGHSA-N 0.000 claims 1
- BWIGSUSEUMXPNK-MJCUULBUSA-N (2R,3S,4S,5S,6R)-2-(hydroxymethyl)-6-[2-methyl-4-(3-methyl-2H-indazol-5-yl)phenoxy]oxane-3,4,5-triol Chemical compound Cc1[nH]nc2ccc(cc12)-c1ccc(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)c(C)c1 BWIGSUSEUMXPNK-MJCUULBUSA-N 0.000 claims 1
- WDFFHFXEWUACJA-GFEQUFNTSA-N (2R,3S,4S,5S,6R)-2-(hydroxymethyl)-6-[2-methyl-5-nitro-4-(2-nitrophenoxy)phenoxy]oxane-3,4,5-triol Chemical compound CC1=CC(OC2=C(C=CC=C2)[N+]([O-])=O)=C(C=C1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)[N+]([O-])=O WDFFHFXEWUACJA-GFEQUFNTSA-N 0.000 claims 1
- IJFNSHLIJCWAJG-KOVVAJLHSA-N (2R,3S,4S,5S,6R)-2-[4-(1-aminoisoquinolin-5-yl)-2-methylphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound Cc1cc(ccc1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)-c1cccc2c(N)nccc12 IJFNSHLIJCWAJG-KOVVAJLHSA-N 0.000 claims 1
- RLXZKGQVICOTPJ-KOVVAJLHSA-N (2R,3S,4S,5S,6R)-2-[4-(1-aminoisoquinolin-7-yl)-2-methylphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [C@H]1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)OC1=C(C=C(C=C1)C1=CC=C2C=CN=C(C2=C1)N)C RLXZKGQVICOTPJ-KOVVAJLHSA-N 0.000 claims 1
- UIOBZAJGQPFERJ-JGLNRKDHSA-N (2R,3S,4S,5S,6R)-2-[4-(3-amino-1H-indazol-5-yl)-2-methylphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound Cc1cc(ccc1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)-c1ccc2[nH]nc(N)c2c1 UIOBZAJGQPFERJ-JGLNRKDHSA-N 0.000 claims 1
- BAGVLHOGIGVWNO-SLHNCBLASA-N 2-[5-methyl-2-nitro-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenoxy]benzonitrile Chemical compound CC1=CC(OC2=C(C=CC=C2)C#N)=C(C=C1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)[N+]([O-])=O BAGVLHOGIGVWNO-SLHNCBLASA-N 0.000 claims 1
- DBMOHJYMORNGSY-FNIAAEIWSA-N 3-(methylcarbamoyl)-5-[3-methyl-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]benzoic acid Chemical compound CNC(=O)C1=CC(=CC(=C1)C(O)=O)C1=CC(C)=C(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)C=C1 DBMOHJYMORNGSY-FNIAAEIWSA-N 0.000 claims 1
- MKTKBNZFKKKJMO-AGRFSFNASA-N 3-[3-cyano-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-N-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(=C1)C1=CC(C#N)=C(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)C=C1 MKTKBNZFKKKJMO-AGRFSFNASA-N 0.000 claims 1
- BUVKOORIXBYWLD-SLHNCBLASA-N 3-[5-methyl-2-nitro-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenoxy]benzonitrile Chemical compound CC=1C(=CC(=C(OC=2C=C(C#N)C=CC=2)C=1)[N+](=O)[O-])O[C@H]1O[C@@H]([C@H]([C@@H]([C@@H]1O)O)O)CO BUVKOORIXBYWLD-SLHNCBLASA-N 0.000 claims 1
- LRTFJRXRGJISBO-SLHNCBLASA-N 4-[5-methyl-2-nitro-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenoxy]benzonitrile Chemical compound CC1=CC(OC2=CC=C(C=C2)C#N)=C(C=C1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)[N+]([O-])=O LRTFJRXRGJISBO-SLHNCBLASA-N 0.000 claims 1
- GFDIUBGDCZXKIR-UHFFFAOYSA-N 5-[3-(3-methylphenyl)phenyl]-2h-tetrazole Chemical compound CC1=CC=CC(C=2C=C(C=CC=2)C2=NNN=N2)=C1 GFDIUBGDCZXKIR-UHFFFAOYSA-N 0.000 claims 1
- QNQFUHVFWRHJRE-KOVVAJLHSA-N 5-[3-methyl-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-2H-isoquinolin-1-one Chemical compound Cc1cc(ccc1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)-c1cccc2c1cc[nH]c2=O QNQFUHVFWRHJRE-KOVVAJLHSA-N 0.000 claims 1
- NHKSUDAJGASANW-KOVVAJLHSA-N 5-[3-methyl-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-N-propan-2-ylpyridine-3-carboxamide Chemical compound CC(C)NC(=O)C1=CC(=CN=C1)C1=CC(C)=C(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)C=C1 NHKSUDAJGASANW-KOVVAJLHSA-N 0.000 claims 1
- XBHYZDSPLLPGBC-GJGATLCTSA-N 5-[3-methyl-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]pyridine-3-carboxylic acid Chemical compound CC1=C(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)C=CC(=C1)C1=CN=CC(=C1)C(O)=O XBHYZDSPLLPGBC-GJGATLCTSA-N 0.000 claims 1
- KZOQVRGVRZMRCJ-FJBDOQBJSA-N 6-[3-methyl-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-1H-thieno[3,2-d]pyrimidine-2,4-dione Chemical compound Cc1cc(ccc1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)-c1cc2[nH]c(=O)[nH]c(=O)c2s1 KZOQVRGVRZMRCJ-FJBDOQBJSA-N 0.000 claims 1
- ZCVUFIIEULABCG-BZDYCCQFSA-N 7-[3-methyl-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-2-propan-2-yl-3,4-dihydroisoquinolin-1-one Chemical compound CC(C)N1CCC2=C(C=C(C=C2)C2=CC(C)=C(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)C=C2)C1=O ZCVUFIIEULABCG-BZDYCCQFSA-N 0.000 claims 1
- PTHYFAHVFNGFOH-BZDYCCQFSA-N 7-[3-methyl-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-2-propan-2-ylisoquinolin-1-one Chemical compound CC(C)N1C=CC2=C(C=C(C=C2)C2=CC(C)=C(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)C=C2)C1=O PTHYFAHVFNGFOH-BZDYCCQFSA-N 0.000 claims 1
- GPRAPUBBCQSVDE-KOVVAJLHSA-N 7-[3-methyl-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-3,4-dihydro-2H-isoquinolin-1-one Chemical compound [C@H]1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)OC1=C(C=C(C=C1)C1=CC=C2CCNC(C2=C1)=O)C GPRAPUBBCQSVDE-KOVVAJLHSA-N 0.000 claims 1
- NLDOAAUAVZGEER-UHFFFAOYSA-N CC(CC(C(N)=O)=C1)(C=C1C1=CC(C)=CC=C1)C(N)=O.Cl Chemical compound CC(CC(C(N)=O)=C1)(C=C1C1=CC(C)=CC=C1)C(N)=O.Cl NLDOAAUAVZGEER-UHFFFAOYSA-N 0.000 claims 1
- GTXGXWLIQNJDAP-MJCUULBUSA-N N-[2-[5-methyl-2-nitro-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenoxy]phenyl]acetamide Chemical compound CC(=O)NC1=C(OC2=C(C=C(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)C(C)=C2)[N+]([O-])=O)C=CC=C1 GTXGXWLIQNJDAP-MJCUULBUSA-N 0.000 claims 1
- XOPAVIQSCDWFEN-MJCUULBUSA-N N-[3-[5-methyl-2-nitro-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC(OC2=C(C=C(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)C(C)=C2)[N+]([O-])=O)=CC=C1 XOPAVIQSCDWFEN-MJCUULBUSA-N 0.000 claims 1
- PBBCIAAVPBHHHB-MJCUULBUSA-N N-[4-[5-methyl-2-nitro-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenoxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=C(OC2=C(C=C(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)C(C)=C2)[N+]([O-])=O)C=C1 PBBCIAAVPBHHHB-MJCUULBUSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- WWZAJMUDBKQTLG-JGLNRKDHSA-N methyl 5-[3-methyl-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]pyridine-3-carboxylate Chemical compound COC(=O)C1=CC(=CN=C1)C1=CC(C)=C(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)C=C1 WWZAJMUDBKQTLG-JGLNRKDHSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
- B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
- B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
- B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
- B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mechanical Engineering (AREA)
- Composite Materials (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662312017P | 2016-03-23 | 2016-03-23 | |
| US62/312,017 | 2016-03-23 | ||
| PCT/US2017/023764 WO2017165619A1 (en) | 2016-03-23 | 2017-03-23 | Mannose-derived antagonists of fimh useful for treating disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018131440A true RU2018131440A (ru) | 2020-04-23 |
| RU2018131440A3 RU2018131440A3 (enExample) | 2020-05-18 |
Family
ID=59900869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018131440A RU2018131440A (ru) | 2016-03-23 | 2017-03-23 | Антагонисты FimH, являющиеся производными маннозы, пригодные для лечения заболевания |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10738070B2 (enExample) |
| EP (1) | EP3432892A4 (enExample) |
| JP (1) | JP2019509315A (enExample) |
| KR (1) | KR20180128937A (enExample) |
| CN (1) | CN108778288A (enExample) |
| AU (1) | AU2017238392A1 (enExample) |
| BR (1) | BR112018069147A2 (enExample) |
| CA (1) | CA3018345A1 (enExample) |
| RU (1) | RU2018131440A (enExample) |
| WO (1) | WO2017165619A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180128937A (ko) | 2016-03-23 | 2018-12-04 | 핌브리온 세러퓨틱스 인코포레이티드 | 질환을 치료하는데 유용한 fimh의 만노스-유래 길항제 |
| US10385087B1 (en) * | 2018-04-26 | 2019-08-20 | National Taipei University Of Technology | Xylose derivatives and process for preparation thereof |
| DK3820856T3 (da) | 2018-07-10 | 2022-10-24 | Glaxosmithkline Ip Dev Ltd | C-Mannosid-forbindelser, der kan anvendes til behandling af urinvejsinfektioner |
| BR112021022281A2 (pt) * | 2019-05-07 | 2021-12-28 | Fimbrion Therapeutics Inc | Novos compostos |
| WO2020254369A1 (en) * | 2019-06-19 | 2020-12-24 | Glaxosmithkline Intellectual Property Development Limited | Substituted biphenyl or phenylheteroaryl-mannosides as antagonists of fimh |
| CN111205344B (zh) * | 2020-01-14 | 2023-03-14 | 华东理工大学 | 一种用于甲醇溶剂识别的纯有机磷光小分子材料及其制备方法 |
| CN113461753B (zh) * | 2020-03-31 | 2023-05-23 | 郑计岳 | 2-炔基甘露糖衍生物及其应用 |
| CN111518738B (zh) * | 2020-05-08 | 2022-02-08 | 徐州海润生物科技有限公司 | 重组卡介苗及其制备方法和应用 |
| CN113797212B (zh) * | 2020-06-11 | 2023-12-22 | 兰州大学 | 一组含有甘露糖结构的抗菌药物的合成方法及活性研究 |
| CN116621891B (zh) * | 2023-05-25 | 2023-10-31 | 齐齐哈尔医学院 | 白鲜酚苷c及其制备方法和其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5122602A (en) | 1989-02-13 | 1992-06-16 | Miles Inc. | Chromogenic merocyanine enzyme substrates |
| DE69433901T2 (de) | 1993-11-18 | 2005-07-28 | Siga Technologies, Inc. | Verbindungen und pharmazeutische zusammensetzungen zur behandlung und prophylaxe bakterieller infektionen |
| US6420127B1 (en) | 1994-11-18 | 2002-07-16 | Washington University | Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections |
| WO2001010386A2 (en) | 1999-08-11 | 2001-02-15 | Washington University | Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof |
| CA2411944C (en) | 2000-06-09 | 2010-12-14 | Baylor College Of Medicine | The combination of antimicrobial agents and bacterial interference to coat medical devices |
| WO2005033059A1 (es) | 2003-10-08 | 2005-04-14 | Innovaprotean, S.L. | Compuestos útiles para el tratamiento de enfermedades asociadas a la formación de fibrilas amiloides |
| EP1755619A2 (en) | 2004-03-23 | 2007-02-28 | VIB vzw | Anti-adhesive compounds to prevent and treat bacterial infections |
| SE528382C2 (sv) | 2004-10-05 | 2006-10-31 | Probi Ab | Probiotiska lactobacillusstammar för förbättrad vaginal hälsa |
| FR2876798A1 (fr) | 2004-10-14 | 2006-04-21 | Univ Clermont Auvergne | Diagnostic et traitement de la maladie de crohn |
| WO2012109263A1 (en) | 2011-02-07 | 2012-08-16 | The Washington University | Mannoside compounds and methods of use thereof |
| EP2490530A4 (en) | 2009-10-22 | 2014-01-22 | Univ Washington | COMPOUNDS AND METHOD FOR THE TREATMENT OF BACTERIAL INFECTIONS |
| NZ616764A (en) | 2009-12-14 | 2014-11-28 | Univ Basel | Mannose derivatives as antagonists of bacterial adhesion |
| WO2012164074A1 (en) | 2011-06-03 | 2012-12-06 | University Of Basel | Mannose phosphate derivatives as antagonists of bacterial adhesion |
| US9890176B2 (en) | 2013-03-12 | 2018-02-13 | Vertex Pharmaceuticals Incorporated | Mannose derivatives for treating bacterial infections |
| ES2959183T3 (es) | 2013-05-30 | 2024-02-21 | Washington University St Louis | Derivados de manosa y su uso en el tratamiento de infecciones bacterianas |
| US20200002303A1 (en) | 2016-03-11 | 2020-01-02 | Fimbrion Therapeutics, Inc. | C-glycoside compounds useful for treating disease |
| KR20180128937A (ko) | 2016-03-23 | 2018-12-04 | 핌브리온 세러퓨틱스 인코포레이티드 | 질환을 치료하는데 유용한 fimh의 만노스-유래 길항제 |
-
2017
- 2017-03-23 KR KR1020187030240A patent/KR20180128937A/ko not_active Ceased
- 2017-03-23 BR BR112018069147A patent/BR112018069147A2/pt not_active Application Discontinuation
- 2017-03-23 RU RU2018131440A patent/RU2018131440A/ru not_active Application Discontinuation
- 2017-03-23 US US16/087,305 patent/US10738070B2/en active Active
- 2017-03-23 JP JP2018549836A patent/JP2019509315A/ja active Pending
- 2017-03-23 CA CA3018345A patent/CA3018345A1/en not_active Abandoned
- 2017-03-23 WO PCT/US2017/023764 patent/WO2017165619A1/en not_active Ceased
- 2017-03-23 AU AU2017238392A patent/AU2017238392A1/en not_active Abandoned
- 2017-03-23 EP EP17771134.8A patent/EP3432892A4/en not_active Withdrawn
- 2017-03-23 CN CN201780019049.3A patent/CN108778288A/zh active Pending
-
2020
- 2020-07-10 US US16/925,977 patent/US20200407390A1/en not_active Abandoned
-
2024
- 2024-09-17 US US18/887,190 patent/US20250009723A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3018345A1 (en) | 2017-09-28 |
| CN108778288A (zh) | 2018-11-09 |
| EP3432892A4 (en) | 2019-10-30 |
| US10738070B2 (en) | 2020-08-11 |
| RU2018131440A3 (enExample) | 2020-05-18 |
| JP2019509315A (ja) | 2019-04-04 |
| BR112018069147A2 (pt) | 2019-01-22 |
| AU2017238392A1 (en) | 2018-09-27 |
| US20190106451A1 (en) | 2019-04-11 |
| WO2017165619A1 (en) | 2017-09-28 |
| US20250009723A1 (en) | 2025-01-09 |
| US20200407390A1 (en) | 2020-12-31 |
| KR20180128937A (ko) | 2018-12-04 |
| EP3432892A1 (en) | 2019-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018131440A (ru) | Антагонисты FimH, являющиеся производными маннозы, пригодные для лечения заболевания | |
| JP2019509315A5 (enExample) | ||
| US11026926B2 (en) | Substituted bicyclic compounds as bromodomain inhibitors | |
| CN104066731B (zh) | 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类 | |
| US9861637B2 (en) | Heterocyclic compounds as bromodomain inhibitors | |
| US9309222B2 (en) | Phenyl linked quinolinyl modulators of RORγt | |
| JP4954086B2 (ja) | １ｈ−ピロロ［２，３−ｂ］ピリジン | |
| JP4673977B2 (ja) | 炎症性疾患治療用フタラジン誘導体 | |
| RU2586974C2 (ru) | Ингибиторы катехол-о-метилтрансферазы и их применение при лечении психотических расстройств | |
| JP3544675B2 (ja) | 血管形成阻害活性を有するフタラジン | |
| US10179125B2 (en) | Substituted pyridines as bromodomain inhibitors | |
| ES2769181T3 (es) | Compuestos de piridina y de pirazina sustituidos como inhibidores de PDE4 | |
| ME02729B (me) | Indolski i indazolski spojevi koji aktiviraju ampk | |
| JP2014513110A5 (enExample) | ||
| JP2014509316A5 (enExample) | ||
| JP2019508504A5 (enExample) | ||
| RU2013141528A (ru) | ИНГИБИТОРЫ РЕЦЕПТОРОВ RORгаммаТ | |
| JP2013510124A5 (enExample) | ||
| HK1246273A1 (en) | Substituted pyridines as bromodomain inhibitors | |
| JP2016512547A (ja) | 線維症疾患の治療のための化合物 | |
| RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
| JP2025517106A (ja) | Ｐａｒｐ１阻害剤としての化合物 | |
| CN107629022B (zh) | 一种抗菌增效剂及其制法和用途 | |
| JP2025500176A (ja) | カルボン酸バイオアイソスタを含むｄｈｏｄｈ阻害剤 | |
| RU2016128365A (ru) | 5-арил-1-имино-1-оксо-[1,2,4]тиадиазины |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210225 |